More than 1.5 billion people around the world are infected with soil-transmitted helminths (STHs), parasitic worms that damage their health and are a leading cause of maln
GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up R&D on infectious diseases that mainly impact lower-income countries.
Professor Paul Kaye from the University of York, whose research team was recently granted €8 million to help reduce the burden of leishmaniasis in African countries, takes us through the lo
The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio